Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Aug
07
New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis
Apr
28
UCB Announces PDUFA Date for Bimekizumab
Apr
23
"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis
Apr
23
UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021
Feb
23
UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development